Supplementary Video S2 from Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer

Huijuan Fan,Zhanao Xu,Ke Yao,Bingxin Zheng,Yuan Zhang,Xuxiang Wang,Tengjiang Zhang,Xuan Li,Haitian Hu,Bin Yue,Zeping Hu,Hanqiu Zheng

DOI: https://doi.org/10.1158/0008-5472.25125052.v1

2024-01-01

Abstract:Supplementary Video S2 is related to Figure 5 (Olaparib-only group).

What problem does this paper attempt to address?

Supplementary Video S1 from Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer

Hua Fan,Zhanao Xu,Ke Yao,Bingxin Zheng,Yuan Zhang,Xuxiang Wang,Tengjiang Zhang,Xuan Li,Haitian Hu,Bin Yue,Zeping Hu,Hanqiu Zheng

DOI: https://doi.org/10.1158/0008-5472.25125055.v1

2024-01-01

Abstract:Supplementary Video S1 is related to Figure 5 (Vehicle-only group).
Supplemental Table S2 from Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer

Huijuan Fan,Zhanao Xu,Ke Yao,Bingxin Zheng,Yuan Zhang,Xuxiang Wang,Tengjiang Zhang,Xuan Li,Haitian Hu,Bin Yue,Zeping Hu,Hanqiu Zheng

DOI: https://doi.org/10.1158/0008-5472.25125061

2024-01-01

Abstract:Metabolomics of primary tumors vs bone metastasis
Supplemental Table S1 from Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer

Huijuan Fan,Zhanao Xu,Ke Yao,Bingxin Zheng,Yuan Zhang,Xuxiang Wang,Tengjiang Zhang,Xuan Li,Haitian Hu,Bin Yue,Zeping Hu,Hanqiu Zheng

DOI: https://doi.org/10.1158/0008-5472.25125064

2024-01-01

Abstract:Metabolomics of macrophages vs osteaoclasts
Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer

Huijuan Fan,Zhanao Xu,Ke Yao,Bingxin Zheng,Yuan Zhang,Xuxiang Wang,Tengjiang Zhang,Xuan Li,Haitian Hu,Bin Yue,Zeping Hu,Hanqiu Zheng

DOI: https://doi.org/10.1158/0008-5472.CAN-23-1443

2024-02-01

Abstract:The majority of patients with late-stage breast cancer develop distal bone metastases. The bone microenvironment can affect response to therapy, and uncovering the underlying mechanisms could help identify improved strategies for treating bone metastatic breast cancer. Here, we observed that osteoclasts reduced the sensitivity of breast cancer cells to DNA damaging agents, including cisplatin and the PARP inhibitor (PARPi) olaparib. Metabolic profiling identified elevated glutamine production by osteoclasts. Glutamine supplementation enhanced the survival of breast cancer cells treated with DNA damaging agents, while blocking glutamine uptake increased sensitivity and suppressed bone metastasis. GPX4, the critical enzyme responsible for glutathione oxidation, was upregulated in cancer cells following PARPi treatment through stress-induced ATF4-dependent transcriptional programming. Increased glutamine uptake and GPX4 upregulation concertedly enhanced glutathione metabolism in cancer cells to help neutralize oxidative stress and generate PARPi resistance. Analysis of paired patient samples of primary breast tumors and bone metastases revealed significant induction of GPX4 in bone metastases. Combination therapy utilizing PARPi and zoledronate, which blocks osteoclast activity and thereby reduces the microenvironmental glutamine supply, generated a synergistic effect in reducing bone metastasis. These results identify a role for glutamine production by bone-resident cells in supporting metastatic cancer cells to overcome oxidative stress and develop resistance to DNA-damaging therapies. Significance: Metabolic interaction between osteoclasts and tumor cells contributes to resistance to DNA-damaging agents, which can be blocked by combination treatment with PARP and osteoclast inhibitors to reduce bone metastatic burden.
Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Lauren A. Byers,Jing Wang,Monique B. Nilsson,Junya Fujimoto,Pierre Saintigny,John S. Yordy,Uma Giri,Michael Peyton,You Hong Fan,Lixia Diao,Fatemeh Masrorpour,Li Shen,Wenbin Liu,Boris Duchemann,Praveen K. Tumula,Vikas Bhardwaj,James Welsh,Stephanie Weber,Bonnie S. Glisson,Neda Kalhor,Ignacio I. Wistuba,Luc Girard,Scott M. Lippman,Gordon B. Mills,Kevin R. Coombes,John N. Weinstein,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/2159-8290.22528434.v1

2023-01-01

Abstract:<p>PDF file, 81K, Effect of PARP inhibition in combination with standard chemotherapy.</p>
Supplementary Data from an Alternatively Spliced P62 Isoform Confers Resistance to Chemotherapy in Breast Cancer

Qianying Guo,Hao Wang,Jiahao Duan,Wenwu Luo,Rongrong Zhao,Yuting Shen,Bijun Wang,Siqi Tao,Yi Sun,Qian Ye,Xiaomin Bi,Hui Yuan,Qiang Wu,Peter E. Lobie,Tao Zhu,Sheng Tan,Xing Huang,Zhengsheng Wu

DOI: https://doi.org/10.1158/0008-5472.22432764.v1

2023-01-01

Abstract:Supplementary Data from An Alternatively Spliced p62 Isoform Confers Resistance to Chemotherapy in Breast Cancer
Osteoclast-Cancer Cell Metabolic Crosstalk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer

Huijuan Fan,Zhanao Xu,Ke Yao,Bingxin Zheng,Yuan Zhang,Xuxiang Wang,Tengjiang Zhang,Xuan Li,Haitian Hu,Bin Yue,Zeping Hu,Hanqiu Zheng

DOI: https://doi.org/10.1158/0008-5472.can-23-1443

IF: 11.2

2023-12-02

Cancer Research

Abstract:The majority of patients with late-stage breast cancer develop distal bone metastases. The bone microenvironment can affect response to therapy, and uncovering the underlying mechanisms could help identify improved strategies for treating bone metastatic breast cancer. Here, we observed that osteoclasts reduced the sensitivity of breast cancer cells to DNA damaging agents, including cisplatin and the PARP inhibitor (PARPi) olaparib. Metabolic profiling identified elevated glutamine production by osteoclasts. Glutamine supplementation enhanced the survival of breast cancer cells treated with DNA damaging agents, while blocking glutamine uptake increased sensitivity and suppressed bone metastasis. GPX4, the critical enzyme responsible for glutathione oxidation, was upregulated in cancer cells following PARPi treatment through stress-induced ATF4-dependent transcriptional programming. Increased glutamine uptake and GPX4 upregulation concertedly enhanced glutathione metabolism in cancer cells to help neutralize oxidative stress and generate PARPi resistance. Analysis of paired patient samples of primary breast tumors and bone metastases revealed significant induction of GPX4 in bone metastases. Combination therapy utilizing PARPi and zoledronate, which blocks osteoclast activity and thereby reduces the microenvironmental glutamine supply, generated a synergistic effect in reducing bone metastasis. These results identify a role for glutamine production by bone-resident cells in supporting metastatic cancer cells to overcome oxidative stress and develop resistance to DNA-damaging therapies.

oncology
Osteoclast-Cancer Cell Metabolic Symbiosis Renders PARP Inhibitor Therapy Resistance in Bone Metastasis

Huijuan Fan,Zhanao Xu,Ke Yao,Bingxin Zheng,Yuan Zhang,Xuxiang Wang,Tengjiang Zhang,Xuan Li,Haitian Hu,Bin Yue,Zeping Hu,Hanqiu Zheng

DOI: https://doi.org/10.1101/2023.08.15.553338

2023-01-01

Abstract:Seventy percent of patients with late-stage breast cancer develop distal bone metastases; however, the mechanism by which the metabolic microenvironment affects resistance to therapy remains unknown. We investigated the metabolic bone microenvironment and identified glutathione metabolism as the top pathway in osteoclasts, which provides feedback to tumor cells to help neutralize oxidative stress and generate PARP inhibitor (PARPi) therapy resistance. GPX4, the critical enzyme responsible for glutathione oxidation, was upregulated during PARPi therapy through stress-induced ATF4-dependent transcriptional programming. The increased absorption of glutamine and the upregulation of GPX4 expression work in concert to enhance glutathione metabolism in cancer cells. Human clinical sample analysis of paired primary breast tumor and bone metastasis samples revealed that GPX4 was significantly induced in bone metastases. Combination therapy utilizing PARPi and zoledronate, which blocks osteoclast activity and thereby reduces the microenvironmental glutamine supply, generates a synergistic effect in reducing bone metastasis. Thus, our results identified an essential metabolic symbiosis between bone-resident cells and metastatic cancer cells during PARPi therapy. SIGNIFICANCE Osteoclast-derived glutamine is taken up by tumor cells to synthesize glutathione and neutralize the ROS generated by PARPi. This is the first example of “metabolic symbiosis” in therapeutic resistance of bone metastasis. ### Competing Interest Statement The authors have declared no competing interest.
Supplementary Video 2 from Bone Metastasis Initiation is Coupled with Bone Remodeling Through Osteogenic Differentiation of NG2+ Cells

Weijie Zhang,Zhan Xu,Xiaoxin Hao,Tiancheng He,Jiasong Li,Yichao Shen,Kai Liu,Yang Gao,Jun Liu,David G. Edwards,Aaron M. Muscarella,Ling Wu,Liqun Yu,Longyong Xu,Xi Chen,Yi-Hsuan Wu,Igor L. Bado,Yunfeng Ding,Sergio Aguirre,Hai Wang,Zbigniew Gugala,Robert L. Satcher,Stephen T.C. Wong,Xiang H.-F. Zhang

DOI: https://doi.org/10.1158/2159-8290.22541704

2023-01-01

Abstract:Supplemantary Video 2, LLC1 cells under monoculture
Differential regulation of breast cancer bone metastasis by PARP1 and PARP2

Hao Zuo,Dengbao Yang,Qiwen Yang,Haidong Tang,Yang-Xin Fu,Yihong Wan

DOI: https://doi.org/10.1038/s41467-020-15429-z

IF: 16.6

2020-03-27

Nature Communications

Abstract:Abstract PARP1 and PARP2 dual inhibitors, such as olaparib, have been recently FDA approved for the treatment of advanced breast and ovarian cancers. However, their effects on bone mass and bone metastasis are unknown. Here we show that olaparib increases breast cancer bone metastasis through PARP2, but not PARP1, specifically in the myeloid lineage, but not in the cancer cells. Olaparib treatment or PARP1/2 deletion promotes osteoclast differentiation and bone loss. Intriguingly, myeloid deletion of PARP2, but not PARP1, increases the population of immature myeloid cells in bone marrow, and impairs the expression of chemokines such as CCL3 through enhancing the transcriptional repression by β-catenin. Compromised CCL3 production in turn creates an immune-suppressive milieu by altering T cell subpopulations. Our findings warrant careful examination of current PARP inhibitors on bone metastasis and bone loss, and suggest cotreatment with CCL3, β-catenin inhibitors, anti-RANKL or bisphosphonates as potential combination therapy for PARP inhibitors.

multidisciplinary sciences
Supplementary Video 4 from Bone Metastasis Initiation is Coupled with Bone Remodeling Through Osteogenic Differentiation of NG2+ Cells

Weijie Zhang,Zhan Xu,Xiaoxin Hao,Tiancheng He,Jiasong Li,Yichao Shen,Kai Liu,Yang Gao,Jun Liu,David G. Edwards,Aaron M. Muscarella,Ling Wu,Liqun Yu,Longyong Xu,Xi Chen,Yi-Hsuan Wu,Igor L. Bado,Yunfeng Ding,Sergio Aguirre,Hai Wang,Zbigniew Gugala,Robert L. Satcher,Stephen T.C. Wong,Xiang H.-F. Zhang

DOI: https://doi.org/10.1158/2159-8290.22541698.v1

2023-01-01

Abstract:Supplemantary Video 4, LLC1 cells cocultured with NG2+ Ncadherin KO BMSCs
Supplementary Figure S7 from Germline Mutations of Holliday Junction Resolvase Genes in Multiple Primary Malignancies Involving Lung Cancer Lead to PARP Inhibitor Sensitization

Haoran Wang,Yuping Chen,Xinshu Wang,Binhao Huang,Juntao Xie,Hui Yin,Jie Yang,Jinhuan Wu,Jian Yuan,Jie Zhang

DOI: https://doi.org/10.1158/1078-0432.25603572.v1

2024-01-01

Abstract:Supplementary Figure S7: Construction of CDX and PDO models.
Table S2 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Binghao Li,Zhan Wang,Hao Wu,Mingfeng Xue,Peng Lin,Shengdong Wang,Nong Lin,Xin Huang,Weibo Pan,Meng Liu,Xiaobo Yan,Hao Qu,Lingling Sun,Hengyuan Li,Yan Wu,Wangsiyuan Teng,Zenan Wang,Xingzhi Zhou,Huabiao Chen,Mark C. Poznansky,Zhaoming Ye

DOI: https://doi.org/10.1158/0008-5472.22419828

2023-01-01

Abstract:Supplementary Table S2. Patient characteristics
Supplementary Figure 2 from Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents

Sharad Sharma,Junying Zeng,Chun-Mei Zhuang,Yong‐Qing Zhou,Hang‐Ping Yao,Xing Hu,Ruiwen Zhang,Ming-Hai Wang

DOI: https://doi.org/10.1158/1535-7163.22497784.v1

2023-01-01

Abstract:PDF file - 68K, Figure S2: Effect of BMS-777607 on breast cancer cell growth and apoptotic death.
Supplementary Figure S1 from Germline Mutations of Holliday Junction Resolvase Genes in Multiple Primary Malignancies Involving Lung Cancer Lead to PARP Inhibitor Sensitization

Haoran Wang,Yuping Chen,Xinshu Wang,Binhao Huang,Juntao Xie,Hui Yin,Jie Yang,Jinhuan Wu,Jian Yuan,Jie Zhang

DOI: https://doi.org/10.1158/1078-0432.25603593.v1

2024-01-01

Abstract:Supplementary Figure S1: The workflow of this study.
Supplementary Figure 1 from Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents

Sharad Sharma,Junying Zeng,Chun-Mei Zhuang,Yong-Qing Zhou,Hang‐Ping Yao,Xing Hu,Ruiwen Zhang,Ming‐Hai Wang

DOI: https://doi.org/10.1158/1535-7163.22497787

2023-01-01

Abstract:PDF file - 63K, Figure S1: Expression of RON and MET by breast cancer MCF-7, T-47D and ZR-75-1 cells.
Supplementary Video 1 from Bone Metastasis Initiation is Coupled with Bone Remodeling Through Osteogenic Differentiation of NG2<sup>+</sup> Cells

Weijie Zhang,Zhan Xu,Xiaoxin Hao,Tiancheng He,Jiasong Li,Yichao Shen,Kai Liu,Yang Gao,Jun Liu,David G. Edwards,Aaron M. Muscarella,WU Li-jun,Liqun Yu,Longyong Xu,Xi Chen,Yi-Hsuan Wu,Igor Bado,Yunfeng Ding,Sergio Aguirre,Hai Wang,Zbigniew Gugala,Robert L. Satcher,Stephen T.C. Wong,Xiang H.-F. Zhang

DOI: https://doi.org/10.1158/2159-8290.22541707

2023-01-01

Abstract:Supplemantary Video 1, LLC1 cells cocultured with NG2+ BMSCs
Figure S5 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Binghao Li,Zhan Wang,Hao Wu,Mingfeng Xue,Peng Lin,Shengdong Wang,Nong Lin,Xin Huang,Weibo Pan,Meng Liu,Xiaobo Yan,Hao Qu,Lingling Sun,Hengyuan Li,Yan Wu,Wangsiyuan Teng,Zenan Wang,Xingzhi Zhou,Huabiao Chen,Mark C. Poznansky,Zhaoming Ye

DOI: https://doi.org/10.1158/0008-5472.22419837.v1

2023-01-01

Abstract:Supplementary figure S5. DAC treatment did not increase the risk of osteosarcoma proliferation.
Supplementary Figure from Pamiparib Monotherapy for Patients with Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study

Xiaohua Wu,Jianqing Zhu,Jing Wang,Zhongqiu Lin,Rutie Yin,Wei Sun,Qi Zhou,Songling Zhang,Danbo Wang,Hong Shi,Yunong Gao,Yi Huang,Guiling Li,Xiuli Wang,Ying Cheng,Ge Lou,Qinglei Gao,Li Wang,Xiuping Du,Mei Pan,Xiyan Mu,Li,Miao Li,Song Mu,Beihua Kong

DOI: https://doi.org/10.1158/1078-0432.22484274

2023-01-01

Abstract:Supplementary Figure from Pamiparib Monotherapy for Patients with Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study

Supplementary Video S2 from Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer

Supplementary Video S1 from Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer

Supplemental Table S2 from Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer

Supplemental Table S1 from Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer

Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer

Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Data from an Alternatively Spliced P62 Isoform Confers Resistance to Chemotherapy in Breast Cancer

Osteoclast-Cancer Cell Metabolic Crosstalk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer

Osteoclast-Cancer Cell Metabolic Symbiosis Renders PARP Inhibitor Therapy Resistance in Bone Metastasis

Supplementary Video 2 from Bone Metastasis Initiation is Coupled with Bone Remodeling Through Osteogenic Differentiation of NG2+ Cells

Differential regulation of breast cancer bone metastasis by PARP1 and PARP2

Supplementary Video 4 from Bone Metastasis Initiation is Coupled with Bone Remodeling Through Osteogenic Differentiation of NG2+ Cells

Supplementary Figure S7 from Germline Mutations of Holliday Junction Resolvase Genes in Multiple Primary Malignancies Involving Lung Cancer Lead to PARP Inhibitor Sensitization

Table S2 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Supplementary Figure 2 from Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents

Supplementary Figure S1 from Germline Mutations of Holliday Junction Resolvase Genes in Multiple Primary Malignancies Involving Lung Cancer Lead to PARP Inhibitor Sensitization

Supplementary Figure 1 from Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents

Supplementary Video 1 from Bone Metastasis Initiation is Coupled with Bone Remodeling Through Osteogenic Differentiation of NG2&lt;sup&gt;+&lt;/sup&gt; Cells

Figure S5 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Supplementary Figure from Pamiparib Monotherapy for Patients with Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study

Supplementary Video 1 from Bone Metastasis Initiation is Coupled with Bone Remodeling Through Osteogenic Differentiation of NG2<sup>+</sup> Cells